Around the Web

Cancer News

Brachytherapy is an efficient treatment for numerous cancer diseases. To support this, the Cancer News regularly inform about related studies and articles as well as cancer demographics. Subscribe to our newsletter to receive the latest news first:
Subscription Cancer News
* Mandatory fields

Cancer News Around the Web

September 05, 2019

Discrepancy between Expectations and Experiences after Prostate Cancer Treatment: A Dutch Multicenter Study

Objectives: To evaluate possible discrepancies between patients’ expectations concerning sexual side effects related to prostate cancer (PCa) treatment, based on the obtained information prior to treatment...

Read More

August 19, 2019

How might financial pressures have impacted brachytherapy? A proposed narrative to explain the declines in cervical and prostate brachytherapy utilization

Rates of brachytherapy administration in the United States have declined for both cervical and prostate cancers, and we argue that the available facts suggest financial considerations are a major contributor to this issue...

Read More

July 30, 2019

Brachytherapy: An overview for clinicians

Brachytherapy is a specific form of radiotherapy consisting of the precise placement of radioactive sources directly into or next to the tumor. This technique is indicated for patients affected by various types of cancers...

Read More

July 01, 2019

125I low-dose-rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer

Radical prostatectomy (RP) and low-dose-rate prostate brachytherapy (LDR) are two widely used treatment options for patients with T1c-T3a prostate cancer. In the present study, the efficacy of the two treatments was compared...

Read More

June 18, 2019

Long-term efficacy and urological toxicity of low-dose-rate brachytherapy (LDR-BT) as monotherapy in localized prostate cancer

Purpose: The purpose of this study was to evaluate the incidence of late severe (≥Grade 3) urinary toxicity and the long-term efficacy after low-dose-rate brachytherapy (LDR-BT) in patients with localized prostate cancer (PCa)...

Read More

June 18, 2019

Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16

Purpose: Prostate cancer (CaP) is the second most common cancer and the fifth leading cause of death from cancer in men in the world [1]. Nowadays, many treatment options available are responsible for side effects, mainly urinary and sexual...

Read More

May 29, 2019

Biochemical outcomes and predictive factors by risk group after permanent iodine-125 seed implantation: Prospective cohort study in 2,316 patients

Purpose: To evaluate the biochemical freedom from failure (bFFF) by risk group and treatment modality and the predictive factors of bFFF by risk group in patients with prostate cancer undergoing permanent seed implantation (PI) with or without external beam radiation therapy (EBRT) in a nationwide prospective cohort study (Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 [I-125] Seed Implantation)...

Read More

May 06, 2019

Role of novel imaging in the management of prostate cancer

This review summarizes novel imaging in the management of prostate cancer including multiparametric MRI, PET-CT scans with different radiotracers including 11C-acetate, 11C-choline, 18F-choline, 18F sodium fluoride, prostate-specific membrane antigen, and anti-1-amino-3-[18F] fluorocyclobutane-1-carboxylic acid (fluciclovine)...

Read More

May 03, 2019

The current state of randomized clinical trial evidence for prostate brachytherapy

Interstitial brachytherapy is one of several curative therapeutic options for the treatment of localized prostate cancer. In this review, we summarize all available randomized data to support the optimal use of prostate brachytherapy...

Read More

May 02, 2019

‘Fake News’ in urology: evaluating the accuracy of articles shared on social media in genitourinary malignancies

Objectives: To evaluate the accuracy of the most popular articles on social media platforms pertaining to genitourinary malignancies, and to identify the prevalence of misinformation available to patients...

Read More

April 03, 2019

Single-fraction brachytherapy as monotherapy for early-stage prostate cancer: The UCSF experience

Purpose: High-dose-rate (HDR) brachytherapy as monotherapy is an effective treatment option for localized prostate cancer, but experience with single-fraction brachytherapy is limited by studies with small sample size. We report a large single-institution experience with single-fraction HDR brachytherapy as monotherapy for early-stage prostate cancer...

Read More

March 16, 2019

Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms

Purpose: To evaluate the long-term urinary outcomes of men with severe pretreatment lower urinary tract symptoms (LUTS) treated with permanent prostate brachytherapy (PPB) ± external beam radiation therapy for localized prostate cancer...

Read More

March 07, 2019

Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds

Purpose: Pulmonary seed emboli to the chest may occur after permanent prostate brachytherapy (PPB). The purpose of this study is to analyze factors associated with seed migration to the chest in a large series of PPB patients from a single institution undergoing implant with either loose seeds (LS), mixed loose and stranded seeds (MS), or exclusively stranded seeds in an absorbable vicryl suture (VS)...

Read More

February 28, 2019

Current state of interventional radiotherapy (brachytherapy) education in Italy: results of the INTERACTS survey

Purpose: Rapid evolution and improvement of technology in radiation oncology and the complexity of each area of radiotherapy (RT) practice determined the need for an adequate and flexible practical training system. In the field of interventional radiotherapy (brachytherapy – BT), a decline in BT utilization was detected in the 1990’s, essentially due to technological improvement of external beam RT...

Read More

February 14, 2019

High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

Prostate cancer is the most common cancer in Canadian adults with prostates and the fourth most common cancer across all Canadians.1 In 2017, there were an estimated 21,300 new cases of prostate cancer diagnosed in Canada and there were an estimated 4,100 deaths...

Read More

February 01, 2019

Combined-modality 125J-seed-brachytherapy, external beam radiation and androgen deprivation therapy of unfavorable-risk prostate cancer: report of outcomes and side-effects

Purpose: To analyze outcomes and complication rates in an unselected cohort of men with unfavorable (NCCN intermediate and high-risk) PCa receiving combined-modality radiation treatment (CRT)...

Read More

January 16, 2019

Impact of a dominant intraprostatic lesion (DIL) boost defined by sextant biopsy in permanent I-125 prostate implants on biochemical disease free survival (bDFS) and toxicity outcomes

Background and purpose: To compare bDFS and toxicity outcomes in a population of intermediate risk prostate cancer patients treated using I-125 LDR brachytherapy with or without DIL boost based on multiple core biopsy maps...

Read More

January 10, 2019

Surgery Versus Radiation for High-risk Prostate Cancer: The Fight Continues. But Is It Time To Call a Draw and Reach Consensus?

Management of high-risk prostate cancer (PC) is one of the most contentious issues that urologists face. Level 1 evidence shows that adding external beam radiotherapy (EBRT) to androgen deprivation therapy (ADT) improves survival outcomes in high-risk and locally advanced PC [1]...

Read More

January 09, 2019

Long-term oncological and functional outcomes support use of low-dose-rate brachytherapy with or without external beam radiation in young men (≤60 years) with localized prostate cancer

PURPOSE: To evaluate the oncological and functional outcomes of young men treated with low-dose-rate brachytherapy (BT) for prostate cancer (PCa)...

Read More

January 09, 2019

A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer

Purpose: External beam radiation therapy (EBRT) with low-dose-rate (LDR) brachytherapy boost has been associated with improved biochemical progression–free survival and overall survival (OS) compared with dose-escalated EBRT (DE-EBRT) alone for unfavorable-risk prostate cancer...

Read More

November 15, 2018

Disadvantageous Socioeconomic Position at Specific Life Periods May Contribute to Prostate Cancer Risk and Aggressiveness

Background: Previous studies on socioeconomic position (SEP) and risk of prostate cancer (PCa) have produced contradictory results. Most measured SEP only once during the individuals' life span. The aim of the study was to identify life course models that describe best the relationship between SEP measured...

Read More

November 08, 2018

Combined Low Dose Rate Brachytherapy and External Beam Radiation Therapy for Intermediate-Risk Prostate Cancer

Introduction: This is a retrospective study conducted to report the tumor control and late toxicity outcomes of patients with intermediate-risk prostate cancer undergoing combination external beam radiation therapy and low dose rate brachytherapy (LDR-PB)...

Read More

November 01, 2018

Brachytherapy Improves 10-year Overall Survival Compared to Prostatectomy Alone in Young Men (≤60) with Low- and Intermediate-Risk Prostate Cancer: An NCDB Analysis

Purpose/Objective(s): The treatment of prostate cancer, weather with prostatectomy, radiation therapy, or active surveillance varies based on risk factors including Gleason score (GS), PSA value and T staging. There is controversy regarding the impact of age on treatment modality choice for those with locally advanced prostate cancer despite the current risk stratification...

Read More

October 31, 2018

Predicting pubic arch interference in permanent prostate brachytherapy based on the specific parameters derived from nuclear magnetic resonance imaging

Purpose: The aim of this study was to establish a more reliable method to predict pubic arch interference (PAI) before permanent prostate brachytherapy...

Read More

October 23, 2018

Patient-reported data confirms efficacy of brachytherapy alone in intermediate risk prostate cancer

Oncology trial RTOG 0232 comparing a combined treatment of external beam therapy and brachytherapy (EBT+B) to transperineal interstitial permanent brachytherapy (B) alone indicate a significantly different clinician and patient-reported late toxicity profile between arms despite similarities in progression-free survival results...

Read More

October 09, 2018

A Prospective Phase II Trial of Trans-perineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiotherapy (NRG Oncology/RTOG -0526)

Purpose: Only retrospective data is available for low dose rate (LDR) salvage prostate brachytherapy for local recurrence after external beam radiotherapy (EBRT). The primary objective of this prospective Phase II trial (NCT00450411) was to evaluate late gastrointestinal and genitourinary adverse events (AEs) after salvage LDR brachytherapy...

Read More

October 04, 2018

Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients

Purpose: To report outcomes of patients undergoing low-dose-rate (LDR) brachytherapy and investigate factors associated with biochemical failure and survival...

Read More

September 25, 2018

Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥60 cc) prostate glands

PURPOSE: Patients with large prostate glands are underrepresented in clinical trials incorporating brachytherapy due to concerns for excessive toxicity. We sought to compare health-related quality of life (HRQOL) outcomes between small (<60 cc) and large (≥60 cc) prostates treated with high-dose-rate brachytherapy (HDR-B)...

Read More

September 20, 2018

Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy

Purpose: To identify patients at extremely low risk of biochemical recurrence (BCR) of prostate cancer after low-dose-rate brachytherapy (LDR-BT) to determine when prostate-specific antigen (PSA) monitoring can be stopped...

Read More

September 11, 2018

Inferring postimplant dose distribution of salvage permanent prostate implant (PPI) after primary PPI on CT images

Purpose: To evaluate the dose distribution of additional radioactive seeds implanted during salvage permanent prostate implant (sPPI) after a primary permanent prostate implant (pPPI)...

Read More

September 11, 2018

Declining brachytherapy utilization for high-risk prostate cancer—Can clinical pathways reverse the trend?

PURPOSE: Although external beam radiation therapy (EBRT) plus a brachytherapy boost (BB) offers a 20% improvement in biochemical progression-free survival compared with dose-escalated EBRT alone for men with intermediate and high-risk prostate cancer, population studies show a concerning decline in BB utilization...

Read More

August 31, 2018

Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease

Purpose: To assess the effectiveness of low-dose-rate (LDR) brachytherapy in patients with localized prostate cancer and to compare the outcome with predictions from Kattan and Partin nomograms at 60 months after seed implantation...

Read More

August 29, 2018

Prostate-specific antigen bounce in patients treated before 60 years old by iodine 125 brachytherapy for prostate cancer is frequent and not a prognostic factor

PURPOSE: The only prognostic factor of prostate-specific antigen (PSA) bounce in prostate cancer found in several studies is young age but has never been specifically studied in this subset of patients for long-term results. Bounce characteristics, histological, clinical, and dosimetric data in young patients were analyzed, as well as their impact on toxicity and survival...

Read More

August 22, 2018

Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer

Purpose: The available data demonstrating that superiority of LDR brachytherapy (LDR-BT) boost in high-risk prostate cancer patients under represents patients with extracapsular extension (T3a) and/or seminal vesicle invasion (T3b) have been limited. We report long-term clinical outcomes data for patients with cT3a/b disease receiving LDR-BT...

Read More

August 01, 2018

Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer

PURPOSE: The recently published ASCENDE-RT randomized clinical trial demonstrated improved biochemical control, albeit with increased toxicity, for a prostate boost with brachytherapy versus external beam radiation therapy alone in patients with intermediate-high risk prostate cancer...

Read More

July 26, 2018

High-volume providers and brachytherapy practice: A Medicare provider utilization and payment analysis

PURPOSE: Brachytherapy is an important component of the treatment of gynecologic and prostate
cancers, with data supporting its impact on clinical outcomes. Prior data have suggested that brachytherapy tends to be focused at high-volume centers. Medicare reimbursement data can provide an understanding of the distribution of brachytherapy cases among billing providers...

Read More

July 18, 2018

High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results

Purpose: To evaluate acute and late genitourinary toxicity, the gastrointestinal toxicity, and the long-term biochemical control after high-dose-rate (HDR) monotherapy in one fraction (20.5 Gy)...

Read More

June 30, 2018

Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: patient reported quality of life outcomes

Purpose: There is limited data to support the use of hypofractionated external beam radiation (HypoF) in combination with high-dose-rate brachytherapy (HDR). We report our quality of life (QOL) outcomes when treating intermediate and high-risk prostate cancer patients with external beam radiation (EBRT) plus HDR...

Read More

June 30, 2018

UK & Ireland Prostate Brachytherapy Practice Survey 2014-2016

Purpose: To document the current prostate brachytherapy practice across the UK and Ireland and compare with previously published audit results...

Read More

June 30, 2018

Low-dose-rate brachytherapy for prostate cancer in renal transplant recipients

Purpose: Prostate cancer (PCa) is the most common malignancy among men and one of the most common neoplasms affecting renal transplant recipients (RTRs). The available treatments for localized PCa among the general population (GP), surgery and external beam radiotherapy, carry a risk of damage to the transplanted kidney, the ureters, and the bladder and therefore tend to be avoided by most groups...

Read More

June 22, 2018

Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival

Background: Investigating oncological outcomes in patients registered in the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) in terms of biochemical relapse-free survival (bRFS) by the Phoenix and the newly developed J-POPS definitions, exploration of predictive factors for bRFS, and preliminary verification of pitfalls of prostate-specific antigen (PSA) failure definitions...

Read More

May 08, 2018

The role of salvage brachytherapy for local relapse after external beam radiotherapy for prostate cancer

Prostate cancer is the most prevalent cancer amongst men. For localized disease, there currently exist several reliable treatment modalities including surgery, radiotherapy and brachytherapy. Our growing understanding of this disease indicates that local control plays a very important role in prevention of subsequent dissemination...

Read More

April 30, 2018

A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes

Purpose: Low-dose-rate (LDR) brachytherapy has been used in Australia since 1998 as curative treatment, either as a boost to external beam radiotherapy (EBRT) or monotherapy in the management of non-metastatic prostate cancer. More recently, the use of Iodine-125 for permanent LDR brachytherapy implants...

Read More

March 30, 2018

Radiation Therapy Research: A Global Analysis 2001-2015

Radiation therapy is a core modality of cancer treatment; however, concerns have been expressed regarding its underutilization and its lack of prioritization as a research domain relative to other cancer treatment modalities, despite its rapid technical evolution...

Read More

March 27, 2018

Prostate segmentation in transrectal ultrasound using magnetic resonance imaging priors

Purpose: In the current standard of care, real-time transrectal ultrasound (TRUS) is commonly used for prostate brachytherapy guidance. As TRUS provides limited soft tissue contrast, segmenting the prostate gland in TRUS images is often challenging and subject to inter-observer and intra-observer variability, especially at the base and apex where the gland boundary is hard to define...

Read More

March 21, 2018

Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review

Radiation therapy (RT) is a curative treatment option for localized prostate cancer. Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule (IDN) is an emerging treatment option that involves the prophylactic irradiation of the whole prostate while increasing RT doses to the visible prostatic tumor...

Read More

March 06, 2018

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer

Question: Is there a difference in prostate cancer–specific mortality and distant metastasis associated with extremely dose-escalated radiotherapy, external beam radiotherapy, or radical prostatectomy in patients with Gleason score 9-10 prostate cancer?

Read More

February 28, 2018

A comparative assessment of inhomogeneity and finite patient dimension effects in 60Co and 192Ir high-dose-rate brachytherapy

Purpose: To perform a comparative study of heterogeneities and finite patient dimension effects in 60Co and 192Ir high-dose-rate (HDR) brachytherapy...

Read More

February 20, 2018

NCCN releases updated guidelines on management of prostate cancer

As it does at least once a year, the National Comprehensive Cancer Network (NCCN) has just released version 1.2018 of its guidelines for physicians on the management of prostate cancer...

Read More

January 18, 2018

Quality of training in radiation oncology in Germany: where do we stand?

Purpose: To evaluate the current situation of young radiation oncologists in Germany with regard to the contents and quality of training and level of knowledge, as well as their working conditions and professional satisfaction...

Read More

Displaying results 1 to 50 out of 131
<< First < Previous 1-50 51-100 101-131 Next > Last >>

Search in Cancer News

GEC-ESTRO Handbook of Brachytherapy:


ABS Brachytherapy Guidelines and Consensus Statements: